TRACON Pharmaceuticals Inc. (TCON): Let’s take a bird-eye on it

0
30

TRACON Pharmaceuticals Inc. (NASDAQ:TCON) changes shares on Tuesday trading session, with a change of 15.48% or $0.26 shares. The trading starts at $1.68 and closed at $1.68 throughout the day. The trading session low price was $1.67 and day high was $2.04 on Tuesday, August 04. After the session, the Healthcare sector daily volume shifted to 3.18 million while its average volume is 467.70K. In other hand, the TCON market cap reached to $11.41M.

On June 30, 2020, BRIEF-Tracon Pharmaceuticals Files Prospectus Related To Sale Of Up To 6.2 Mln Shares Of Common Stock. According to the news reported on Reuters, * TRACON PHARMACEUTICALS – FILES PROSPECTUS RELATED TO SALE OF UP TO 6.2 MILLION SHARES OF CO’S COMMON STOCK BY ASPIRE CAPITAL FUND LLC Source text (https://bit.ly/3dNBkof) Further company coverage:

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 14.12% and up 4.86% for month. Its quarterly performance was 2.65% above, while its half year performance is down -49.87%. TCON yearly performance stood at negative -52.99% and fall -17.09% for year-to-date. Current recommendation for TRACON Pharmaceuticals Inc. is 2.20.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. TCON EPS (TTM) for 12-month is -5.87. EPS for this year is 42.40%, while for the next year its value is -3.12. Its EPS Q/Q reached 67.80%. It has an EPS of -4.90% down for past five years.

Let’s take a look on the analyst recommendations on TCON for the current month and previous month. For the current month, 1 of 3 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 2 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $3.00 – $4.00. Average target price for TCON was reached at $3.50.

The insider ownership moved to 1.40% and institutional holding shifted to 26.30%.

The company posted an EPS (TTM) of -5.87. According to the most recent quarter report on (Jun 2020), 3 analysts estimated an average EPS of -0.73, while -2.1 EPS posted a year ago period. Analyst Estimated EPS for TCON published in the report was -$0.74 – -$0.71 during the same period. Comparing with last year, the average estimated EPS was -2.1 which is lower than -0.78 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for TCON fall -24.52% for period of 200 days. SMA for 50 days was -1.07% which is showing red signal, while SMA-20 was 5.87%. The moving average value for TRACON Pharmaceuticals Inc. (TCON) is 2.3284 and 1.8988 for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in TCON stock. On Jun 24, THEUER CHARLES, President and CEO, bought 9,895 trading shares at the cost of $1.90, which valued at 18801.0. On Jun 15, PELLETIER SAUNDRA L, Director, bought 3,000 shares at the cost of $2.07, with total shares of 5,500. On Jun 11, PELLETIER SAUNDRA L, Director, bought 2,500 shares at the cost of 2.00. After this transaction, PELLETIER SAUNDRA L total shares reached to 2,500 which valued at 5000.0.